H. Lundbeck Has Agreed To Acquire Longboard Pharmaceuticals For $60 Per Share In Cash. The Transaction Is Valued At Approximately $2.6B Equity Value And $2.5B On A Fully Diluted Basis
Portfolio Pulse from Benzinga Newsdesk
H. Lundbeck has agreed to acquire Longboard Pharmaceuticals for $60 per share in cash, valuing the transaction at approximately $2.6 billion in equity value and $2.5 billion on a fully diluted basis.
October 14, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals is being acquired by H. Lundbeck for $60 per share, valuing the deal at $2.6 billion. This acquisition is likely to positively impact LBPH's stock price in the short term.
The acquisition price of $60 per share is likely above the current market price, which should lead to an increase in LBPH's stock price as investors react to the premium being offered. The deal's valuation at $2.6 billion indicates a significant transaction, further supporting a positive impact on the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100